Trexquant Investment LP Invests $1.35 Million in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Trexquant Investment LP has acquired a new position in NewAmsterdam Pharma, purchasing 66,102 shares valued at approximately $1.35 million, representing about 0.06% of the company's stock.
• Wall Street analysts have set a positive outlook for NewAmsterdam Pharma, with multiple firms initiating coverage and ratings ranging from "buy" to "overweight," targeting prices between $39.00 and $44.00.
• Insider trading reveals activity from company executives, including a significant sale of shares by COO Douglas F. Kling, which could indicate a reduction in confidence among top officials despite the stock's recent growth.

Trexquant Investment LP bought a new stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 66,102 shares of the company's stock, valued at approximately $1,353,000. Trexquant Investment LP owned approximately 0.06% of NewAmsterdam Pharma as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of NewAmsterdam Pharma by 19.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after acquiring an additional 596 shares in the last quarter. Northern Trust Corp acquired a new position in shares of NewAmsterdam Pharma during the 4th quarter valued at about $556,000. Barclays PLC increased its stake in shares of NewAmsterdam Pharma by 120.0% during the 4th quarter. Barclays PLC now owns 16,713 shares of the company's stock valued at $429,000 after acquiring an additional 9,117 shares during the last quarter. Arizona State Retirement System acquired a new stake in NewAmsterdam Pharma in the first quarter valued at approximately $215,000. Finally, California State Teachers Retirement System grew its position in NewAmsterdam Pharma by 23.5% in the fourth quarter. California State Teachers Retirement System now owns 19,404 shares of the company's stock valued at $499,000 after acquiring an additional 3,694 shares in the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, COO Douglas F. Kling sold 100,000 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the transaction, the chief operating officer directly owned 44,000 shares of the company's stock, valued at $848,760. This represents a 69.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $24.29, for a total value of $1,214,500.00. Following the completion of the sale, the insider owned 119,302 shares of the company's stock, valued at $2,897,845.58. The trade was a 29.53% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 14,095 shares of company stock worth $279,621 and have sold 424,954 shares worth $9,773,906. Company insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock traded down $0.30 on Thursday, hitting $26.60. 2,254,819 shares of the company's stock traded hands, compared to its average volume of 880,425. The company has a fifty day moving average of $23.58 and a two-hundred day moving average of $20.77. The company has a market capitalization of $3.00 billion, a price-to-earnings ratio of -16.42 and a beta of -0.01. NewAmsterdam Pharma Company N.V. has a one year low of $14.06 and a one year high of $27.35.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The company had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. Equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

NAMS has been the topic of a number of recent research reports. Citigroup started coverage on NewAmsterdam Pharma in a research note on Tuesday, June 17th. They issued a "buy" rating and a $42.00 target price on the stock. Wells Fargo & Company started coverage on NewAmsterdam Pharma in a research note on Monday, August 25th. They issued an "overweight" rating and a $45.00 price target for the company. Royal Bank Of Canada upped their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an "outperform" rating in a report on Thursday, August 7th. Needham & Company LLC reiterated a "buy" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Finally, Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $41.55.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.